Catalent Anagni

Catalent Anagni is a premier contract development and manufacturing organization (CDMO) facility located in Anagni, Italy. Originally a Bristol Myers Squibb manufacturing hub, the site was acquired by Catalent in 2020 to significantly expand its European biologics and oral dose production capacity. The facility specializes in sterile fill/finish, large-scale biologics manufacturing, and oral solid dose packaging and distribution. It gained international prominence as a critical manufacturing site for COVID-19 vaccines, including those developed by AstraZeneca and Johnson & Johnson. The site offers comprehensive services ranging from clinical trial supply to large-scale commercial production for global pharmaceutical and biotechnology clients. With advanced capabilities in lyophilization and automated inspection, Catalent Anagni serves as a strategic hub for complex injectable products.